The Most Important Idea In AI: Recursive Self Improvement

Recursive self improvement is the key to solving intelligence. Human intelligence is built on our ability to characterize the ...
CNBC

Recursion Pharmaceuticals CEO explains how AI could make drug development faster and less costly

Monday - Friday, 6:00 - 7:00 PM ET In a Friday interview with CNBC's Jim Cramer, Recursion Pharmaceuticals CEO Chris Gibson discussed how his company is using artificial intelligence and machine ...
ZDNet

The subtle art of really big data: Recursion Pharma maps the body

Whenever machine learning is applied to a given field of industry, defining the objective is one of the most salient questions. Just what are you trying to find out? In the biological sciences, that ...
The Motley Fool

Down 57% in 2024, Is Recursion Pharmaceuticals a Buy on the Dip?

Recursion Pharmaceuticals is a TechBio company trying to apply artificial intelligence (AI) to the new drug-discovery process. The first placebo-controlled trial results from Recursion Pharmaceuticals ...
Nasdaq

Is Recursion Pharmaceuticals a Buy Ahead of Its Merger With Exscientia?

It's been a rough few years for investors excited about new biopharmaceutical companies that use artificial intelligence (AI) to select new drug candidates. Less than three years after raising $510 ...
CNBC

Recursion CEO Chris Gibson talks integrating AI into drug development process

Chris Gibson, Recursion Pharmaceuticals CEO, joins 'Closing Bell Overtime' to talk its partnership with Nvidia, its investors day, drug discovery and more. Got a confidential news tip? We want to hear ...
Nasdaq

Sudden Ascent: Is Recursion Pharmaceuticals NVIDIA’s AI Favorite?

The market is viewing NVIDIA's decision to keep its 7.7 million share stake in Recursion while divesting from other AI holdings as a significant strategic move. This decision indicates NVIDIA's ...